Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01923987
Other study ID # K-1208-001-002
Secondary ID KCT0000525K-1208
Status Recruiting
Phase Phase 2
First received
Last updated
Start date August 2012
Est. completion date December 2022

Study information

Verified date September 2019
Source Korea Cancer Center Hospital
Contact Sun Mi Moon, MD, PhD
Phone 82-2-970-1237
Email msm386@yahoo.co.kr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Radical treatment of primary rectal cancer with synchronous distant metastases includes surgical resection of primary and metastatic lesion. However, primary rectal cancer in case of metastasized disease are often locally advanced disease and need downsizing before surgery. It is reported that pelvic recurrence rates and distant metastasis rates outside liver are 30~35% and 60%, respectively. Therefore, combined treatment with radiotherapy and chemotherapy is used. However, the sequence of treatment modalities is not yet definitely established and preoperative chemoradiotherapy and surgical resection is accepted as an option of treatment. Conventional long course chemoradiotherapy delays administration of full-dose chemotherapy, and metastatic lesion can be progressed during chemoradiotherapy. In present study, we evaluate the efficacy of short course radiotherapy (SCRT) followed by full-dose chemotherapy with delayed surgical resection of the primary tumor and metastases.


Recruitment information / eligibility

Status Recruiting
Enrollment 39
Est. completion date December 2022
Est. primary completion date December 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Pathologically confirmed adenocarcinoma of rectum

- Lower margin of tumor within 12 cm from anal verge

- Clinically locally advanced (T3-4 or N1-2) disease

- Potentially resectable and synchronous distant metastases in liver and/or lung. The resectability of metastatic lesions is determined by size, number, location, general condition, liver function, and lung function.

- Over 18 years

- Eastern Cooperative Oncology Group performance status 0-2

- Proper organ function (Hemoglobin = 10 g/dl, Absolute neutrophil count (ANC) = 1,500/mm3, Platelet = 100,000/mm3, Creatinine = 1.5 mg/dl, Clearance of creatinine >50 ml/min using Cockcroft-Gault formula, Bilirubin = 1.5 x upper limit of normal (ULN), Liver enzyme (Aspartate aminotransferase/Alanine transaminase/Alkaline phosphatase) = 2.5 x ULN)

- Subject who should sign on the informed consent form before participate the trial.

Exclusion Criteria:

- Metastases in other organ except liver or lung

- History of other type of malignancies within 3 years other than non-melanoma of the skin or carcinoma in situ of cervix

- Hereditary colorectal cancer (FAP, HNPCC, and etc)

- Bowel obstruction or impending bowel obstruction

- Uncontrolled severe illness, unsuitable to chemoradiotherapy (within 6 months, myocardial infarct, unstable angina, heart failure, uncontrolled arrhythmia, uncontrolled epilepsy, central nervous system disease, psychological disorder, and etc)

- Subject pregnant or breast feeding, or incapable of appropriate contraception

- Unresected synchronous colorectal cancer

- History of prior pelvic radiotherapy

- History of prior chemotherapy for colorectal cancer

- Great surgery within 4 week before study enrollment

- Participant in other trial within 4 week before study enrollment

Study Design


Intervention

Radiation:
Short Course Radiotherapy
Radiotherapy to tumor and draining lymph node with 25 Gy in 5 fractions within 5 working days
Drug:
Chemotherapy
Oxaliplatin 85 mg/m2 IV over 2 hrs on Day 1 Irinotecan 180 mg/m2 IV over 30-90 mins on Day 1 Leucovorin 400 mg/m2 IV over 2 hrs on Day 1 and 2 5-fluorouracil bolus 400 mg/m2 IV push on Day 1 and 2 (or 5-fluorouracil infusion 600 mg/m2 IV continuous infusion over 22 hrs). Bevacizumab 5 mg/kg IV over 90 mins on Day 1 Cetuximab (only for patients with K-ras wild type and positive EGFR mutation) 400 mg/m2 IV over 2 hrs on Day 1, and 250 mg/m2 IV over 1 hr on Day 8, 15, 22, 29, and 36. FOLFOX or FOLFIRI (+-Bevacizumab ) repeats every 14 days for up to 3 courses. Cetuximab repeats every week for up to 6 courses Postoperative FOLFOX or FOLFIRI (+-Bevacizumab or Cetuximab) for up to 9 cycles (total 12 cycles)
Procedure:
Delayed Surgery
If primary tumor and metastases is resectable after FOLFOX or FOLFIRI (+-Bevacizumab or Cetuximab) of 3 cycles, patients have surgical resection (and/or radiofrequency ablation to metastases).

Locations

Country Name City State
Korea, Republic of Korea Cancer Center Hospital Seoul
Korea, Republic of Kyung Hee University Gangdong Hospital Seoul

Sponsors (12)

Lead Sponsor Collaborator
Korea Cancer Center Hospital Catholic University of Korea, Seoul St. Mary`s Hospital, Catholic University of Korea, Yeouido St. Mary`s Hospital, Chungnam National University Hospital, Dongtan Sacred Heart Hospital, Gachon University Gil Medical Center, Gangnam Severance Hospital, Kyung Hee University Hospital at Gangdong, Pusan National University Yangsan Hospital, Severance Hospital, The Koreran Society of Coloproctology, Wonju Severance Christian Hospital

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary R0 resection rate R0 resection rate of primary and metastatic lesions Expected average of 12 weeks (after resection)
Secondary Overall survival rate From the first date of radiotherapy to the date of death or last follow-up 2 years
Secondary Progression free survival rate From the first date of radiotherapy to the date of first failure or last follow-up 2 years
Secondary Tumor regression grade Tumor regression grade of primary lesion Just after resection & pathologic report
Secondary Toxicity Adverse events using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT06380101 - Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC) N/A
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Recruiting NCT04323722 - Impact of Bladder Depletion on Mesorectal Movements During Radiotherapy in Rectal Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04088955 - A Digimed Oncology PharmacoTherapy Registry
Active, not recruiting NCT01347697 - Collagen Implant (Biological Mesh) Versus GM Flap for Reconstruction of Pelvic Floor After ELAPE in Rectal Cancer N/A
Recruiting NCT04495088 - Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer Phase 3
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Terminated NCT01347645 - Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer Phase 1/Phase 2
Not yet recruiting NCT03520088 - PROSPECTIVE CONTROLLED AND RANDOMIZED STUDY OF THE GENITOURINARY FUNCTION AFTER RECTAL CANCER SURGERY IN RELATION TO THE DISSECTION OF THE INFERIOR MESENTERIC VESSELS N/A
Recruiting NCT05556473 - F-Tryptophan PET/CT in Human Cancers Phase 1
Recruiting NCT04749381 - The Role of TCM on ERAS of Rectal Cancer Patients Phase 2
Enrolling by invitation NCT05028192 - Mitochondria Preservation by Exercise Training: a Targeted Therapy for Cancer and Chemotherapy-induced Cachexia
Recruiting NCT03283540 - Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence
Completed NCT04534309 - Behavioral Weight Loss Program for Cancer Survivors in Maryland N/A
Recruiting NCT05914766 - An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer N/A
Recruiting NCT04852653 - A Prospective Feasibility Study Evaluating Extracellular Vesicles Obtained by Liquid Biopsy for Neoadjuvant Treatment Response Assessment in Rectal Cancer
Recruiting NCT03190941 - Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients Phase 1/Phase 2
Completed NCT02810652 - Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection N/A
Terminated NCT02933944 - Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer Phase 1